Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07022496

Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals

Caffeine extracted from green tea to abort acute attack of Migraine

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Migraine Brain Diseases Central Nervous System Diseases Headache Disorders Headache Disorders, Primary Migraine Disease Migraine Disorders Migraine Headache Migraine Headache, With or Without Aura Migraine, Acute Nervous System Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

About this study

Caffeine tablets extracted from green tea can be used as caffeinated drinks to decrease intensity of migraine attacks

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study.

Exclusion criteria

Patients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded

Treatment and study plan

Caffeine (200 mg)

Drug

caffeine tablets

Triptans

Drug

Sumatriptan

NSAID (Nonsteroidal anti-inflammatory drugs)

Drug

Aspirin 250 mg, 81 mg, 75 mg

Paracetamol (acetaminophen)

Drug

Paracetamol 250 mg

Primary outcomes

  1. To reduce the severity of migraine attack

    Time frame: Three years

    using Visual analogue scale

Secondary outcomes

  1. To evaluate the effect of oral caffeine in reducing pain associated with acute migraine attacks among patients attending Headache Clinic, Ain Shams University hospital via Visual analogue scale

    Time frame: Three year

    To assess the pain reduction through visual analogue scale

Study contacts

Contact information is provided by the study sponsor or research team.

Diaa Marzouk Abdelhamid, PhD

CONTACT

[email protected]

00201200678440

Nourhan Nader Elguindy, Masters degree

CONTACT

[email protected]

00201128215952

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Assessment of Oral Caffeine Intake in Reducing the Severity of Acute Migraine Attack Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals: A Randomized Controlled Trial

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jun 15, 2025
Registry last updated
Jun 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.